Expert NetworkExpert InterviewNVS

Slingshot members are talking to an expert! The topic is:

Digging into the Phase 3 trial of Novartis' Pluvicto (Lu-PSMA-617) in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) as presented at ESMO 2023

Executed on:Nov 14, 2023 10:00 AM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: UCLA
  • Director of Clinical Research and Associate Professor of Translation Theranostics at UCLA.
  • Manages 15 patients with metastatic castration resistant prostate cancer.
  • Research focuses on translatable radiolabeled theranostic pairs that can be applied for diagnosis and therapy of cancer.

Interview Goal

This call will feature an analysis of the current data available regarding Pluvicto as a treatment for metastatic castration resistant prostate cancer, and will also discuss the recent data which was presented at ESMO 2023.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.